We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Industry Surprised by Proposed Biosimilar Exclusivity Period
Industry Surprised by Proposed Biosimilar Exclusivity Period
February 18, 2011
The drug industry and stakeholders have been taken aback by a measure in President Barack Obama’s proposed fiscal 2012 budget that would lower the exclusivity period for generic biologics from 12 to seven years.